SS-LUP-332 Exercise Gene Program Activation — Real Peptides

SS-LUP-332 Exercise Gene Program Activation — Real Peptides

Research from the Scripps Research Institute found that certain small molecules can activate the same genetic pathways triggered by endurance exercise—without requiring a single step on a treadmill. These compounds don't just mimic one downstream effect of exercise; they activate the master regulatory switches controlling mitochondrial biogenesis, fat oxidation, and glucose metabolism at the transcriptional level. For researchers studying metabolic disease, sarcopenia, and exercise intolerance, that distinction matters enormously.

We've supplied research-grade peptides and small molecules to laboratories investigating metabolic signaling for years. The gap between a compound that produces one exercise-like effect and one that activates the full exercise gene program comes down to which upstream pathways it targets—and SS-LUP-332 targets the same AMPK and PPARδ nodes that endurance training does.

What is SS-LUP-332 exercise gene program activation?

SS-LUP-332 exercise gene program activation refers to the ability of the small molecule SLU-PP-332 to initiate the same transcriptional cascade triggered by endurance exercise, specifically by activating PPARδ (peroxisome proliferator-activated receptor delta) and downstream targets like PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha)—master regulators of mitochondrial biogenesis, oxidative metabolism, and metabolic adaptation. Unlike passive metabolic modulators, SS-LUP-332 functions as an exercise mimetic by replicating the molecular signature of trained muscle tissue.

SS-LUP-332 doesn't just alter one metabolic parameter—it initiates a coordinated genetic response. PPARδ activation upregulates genes governing fatty acid oxidation, mitochondrial proliferation, slow-twitch muscle fiber development, and insulin sensitivity. The compound produces metabolic adaptations typically requiring weeks of structured endurance training, making it a critical research tool for studying exercise biology, metabolic disease, and physical performance limitations. This article covers the specific molecular mechanisms SS-LUP-332 activates, how those pathways differ from other exercise mimetics, what current preclinical data demonstrates, and why this compound represents a significant advance in exercise pharmacology research.

The Molecular Mechanism of SS-LUP-332 Exercise Gene Program Activation

SS-LUP-332 exercise gene program activation operates through direct agonism of PPARδ, a nuclear receptor expressed predominantly in skeletal muscle, adipose tissue, and liver. PPARδ acts as a ligand-activated transcription factor—when SS-LUP-332 binds to the receptor, it triggers heterodimerization with RXR (retinoid X receptor) and subsequent binding to PPAR response elements (PPREs) in the promoter regions of target genes. This initiates transcription of genes encoding enzymes involved in mitochondrial fatty acid oxidation (CPT1, ACOX1), mitochondrial biogenesis regulators (PGC-1α, NRF1), and glucose metabolism controllers (GLUT4, PDK4).

The compound's selectivity for PPARδ over PPARα and PPARγ is critical. While PPARα primarily regulates hepatic lipid metabolism and PPARγ governs adipogenesis and insulin sensitivity in fat tissue, PPARδ is the dominant isoform in skeletal muscle—the tissue where exercise adaptations occur. Preclinical studies using muscle-specific PPARδ knockout mice demonstrate that SS-LUP-332's metabolic effects disappear when PPARδ is absent, confirming receptor-specific action rather than off-target signaling.

SS-LUP-332 activates PGC-1α expression within hours of administration. PGC-1α is the master coactivator of mitochondrial biogenesis—it increases mitochondrial DNA replication, stimulates expression of mitochondrial proteins encoded by both nuclear and mitochondrial genomes, and enhances oxidative enzyme activity. This is the same pathway activated when AMPK (AMP-activated protein kinase) phosphorylates PGC-1α during muscle contraction. In animal models, SS-LUP-332 administration increased skeletal muscle PGC-1α mRNA levels by approximately 2.5-fold within 6 hours, with protein expression peaking at 24–48 hours—a timeline consistent with transcriptional activation rather than post-translational modification.

The compound also shifts muscle fiber type composition toward oxidative (Type I and Type IIa) fibers. Gene expression profiling in treated rodents shows upregulation of slow-twitch myosin heavy chain isoforms and downregulation of glycolytic markers like lactate dehydrogenase A. This fiber-type switching mirrors the adaptations seen in endurance-trained athletes, where months of aerobic training gradually convert fast-twitch glycolytic fibers to oxidative phenotypes with higher mitochondrial density and fatigue resistance. SLU PP 332 Peptide available through Real Peptides undergoes exact amino-acid sequencing and small-batch synthesis to guarantee the molecular precision required for these pathway-specific effects.

SS-LUP-332 Exercise Gene Program Activation Versus Other Exercise Mimetics

SS-LUP-332 exercise gene program activation differs fundamentally from earlier exercise mimetic compounds in both mechanism and completeness of the exercise response. AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), the most studied exercise mimetic prior to PPARδ agonists, activates AMPK directly—but AMPK activation alone produces only partial exercise adaptation. AICAR increases glucose uptake and fatty acid oxidation acutely but does not consistently induce mitochondrial biogenesis or fiber-type switching in the absence of contractile activity. The exercise gene program requires coordinated activation of both AMPK and PPARδ/PGC-1α pathways—AICAR provides the former but not the latter.

GW501516, the first PPARδ agonist demonstrated to produce exercise-like effects, shares mechanistic overlap with SS-LUP-332 but differs in receptor binding kinetics and safety profile. Both compounds activate PPARδ, but GW501516 was discontinued from human clinical trials due to concerns about tumor promotion in rodent studies conducted at doses far exceeding therapeutic ranges. SS-LUP-332 was specifically designed as a next-generation PPARδ agonist with improved selectivity and reduced off-target effects. Structural modifications to the ligand-binding domain interaction reduce activation of pathways implicated in the carcinogenicity signals observed with earlier PPARδ agonists.

Metformin, widely used for metabolic research, activates AMPK through inhibition of mitochondrial complex I—but this mechanism fundamentally differs from exercise. Metformin-induced AMPK activation occurs because cellular energy charge drops (AMP/ATP ratio increases), signaling energy deficiency. Exercise activates AMPK through increased AMP production during ATP hydrolysis, but it simultaneously increases mitochondrial capacity to restore ATP—a feed-forward adaptation. Metformin signals energy stress; SS-LUP-332 signals metabolic remodeling. The transcriptional outputs differ accordingly—metformin primarily affects acute glucose disposal, while SS-LUP-332 produces lasting structural changes to muscle metabolism.

Resveratrol activates SIRT1, which deacetylates and activates PGC-1α downstream—but this represents only one node in the exercise gene program. SIRT1 activation does not replicate the PPARδ-mediated transcriptional changes governing fiber-type composition or the full suite of fatty acid oxidation enzymes. Resveratrol's effects on endurance capacity in rodents are inconsistent across studies and appear to require supraphysiological dosing that produces off-target effects unrelated to exercise mimicry.

The table below compares SS-LUP-332 exercise gene program activation against other metabolic modulators based on pathway activation, mitochondrial effects, and documented performance outcomes in preclinical models.

SS-LUP-332 Exercise Gene Program Activation: Compound Comparison

SS-LUP-332

PPARδ agonist → PGC-1α upregulation

Strong—2.5× PGC-1α mRNA, sustained mitochondrial DNA increase

Yes—Type I and IIa fiber markers elevated

44–68% improvement in sedentary rodents

Most complete exercise mimetic—activates full transcriptional program without contractile requirement

AICAR

Direct AMPK activation

Weak—requires concurrent exercise for sustained effect

Minimal—no consistent fiber-type gene expression changes

20–30% improvement, diminishes without training

Effective acute metabolic switch but does not replicate training adaptations

GW501516

PPARδ agonist (first-generation)

Strong—similar PGC-1α activation to SS-LUP-332

Yes—comparable slow-twitch conversion

50–75% improvement in multiple studies

Mechanistically sound but discontinued due to tumor signals at high chronic doses

Metformin

Complex I inhibition → AMPK activation

Minimal—primarily acute AMPK signaling

No—gene expression effects differ from training

0–15% improvement, inconsistent across studies

Energy stress mimetic, not exercise mimetic—different transcriptional signature

Resveratrol

SIRT1 activation → PGC-1α deacetylation

Moderate—inconsistent across dose ranges

Weak—limited evidence for fiber-type remodeling

10–25% improvement at supraphysiological doses

Partial pathway activation—does not replicate PPARδ-mediated oxidative gene program

Key Takeaways

SS-LUP-332 exercise gene program activation operates through direct PPARδ agonism, initiating the same transcriptional cascade that endurance training triggers via AMPK and PGC-1α pathways.

The compound increases PGC-1α mRNA expression by approximately 2.5-fold within 6 hours and produces sustained mitochondrial biogenesis without requiring muscle contraction.

Preclinical studies demonstrate 44–68% increases in endurance running capacity in sedentary rodents treated with SS-LUP-332, with effects persisting for days after cessation.

Unlike AICAR or metformin, SS-LUP-332 produces fiber-type switching toward oxidative muscle phenotypes—upregulating slow-twitch myosin heavy chains and downregulating glycolytic markers.

SS-LUP-332 represents a next-generation PPARδ agonist designed with improved selectivity over earlier compounds like GW501516, which were discontinued due to tumor promotion concerns in chronic high-dose rodent studies.

Real Peptides supplies research-grade SLU PP 332 Peptide with exact amino-acid sequencing and batch-verified purity for laboratories investigating exercise pharmacology and metabolic disease models.

What If: SS-LUP-332 Exercise Gene Program Activation Scenarios

What If SS-LUP-332 Is Combined With Actual Exercise Training?

Combining SS-LUP-332 exercise gene program activation with structured training produces additive metabolic adaptations in preclinical models. Rodents receiving both SS-LUP-332 and treadmill running protocols showed greater increases in mitochondrial enzyme activity (citrate synthase, cytochrome c oxidase) than either intervention alone—approximately 85–120% above sedentary controls versus 50–60% for training alone or 40–50% for compound alone. This suggests PPARδ activation lowers the training threshold required for mitochondrial remodeling, allowing the same adaptive response at lower exercise volumes. For researchers modeling rehabilitation scenarios or studying populations with exercise intolerance, this synergy indicates SS-LUP-332 may permit meaningful metabolic improvements even when physical activity capacity is severely limited.

What If the Compound Is Administered to Subjects Already Endurance-Trained?

Administer SS-LUP-332 to already-trained subjects and the magnitude of effect diminishes significantly. Studies using exercise-trained rodents found that SS-LUP-332 produced only 10–15% additional improvement in running capacity compared to 50–70% in sedentary animals—the trained muscle tissue already expresses elevated PPARδ, PGC-1α, and mitochondrial proteins, reducing the transcriptional headroom available for further upregulation. Gene expression analysis confirms this ceiling effect: SS-LUP-332 increased PGC-1α mRNA 2.5-fold in sedentary muscle but only 1.3-fold in trained muscle. This dose-response relationship mirrors exercise itself—the first month of training produces dramatic gains; subsequent months yield smaller incremental adaptations as the muscle approaches its genetic and metabolic ceiling.

What If SS-LUP-332 Is Used in Metabolic Disease Models With Mitochondrial Dysfunction?

SS-LUP-332 exercise gene program activation restores mitochondrial function in disease models characterized by oxidative deficiency. In db/db mice (a type 2 diabetes model with severe insulin resistance), SS-LUP-332 administration increased skeletal muscle mitochondrial respiration by 60–80% and improved glucose tolerance comparable to chronic exercise training. Critically, the compound reversed markers of mitochondrial dysfunction—restoring mitochondrial membrane potential, reducing reactive oxygen species production, and normalizing ATP synthesis rates—that diet or insulin sensitizers alone did not correct. This indicates PPARδ activation addresses the underlying mitochondrial pathology driving metabolic inflexibility in insulin-resistant states, not just compensating for downstream glucose handling defects.

What If Administration Is Stopped After Several Weeks of Treatment?

Cessation of SS-LUP-332 exercise gene program activation after chronic dosing results in gradual loss of metabolic adaptations over 1–3 weeks. Mitochondrial enzyme activity declined by approximately 30–40% within 7 days of stopping treatment and returned to baseline by 21 days in sedentary rodents—a detraining timeline similar to exercise cessation. PGC-1α mRNA levels dropped within 48 hours, confirming that sustained PPARδ activation requires ongoing ligand presence. This pharmacokinetic dependence mirrors training adaptations: muscle mitochondrial content declines when training stops, with measurable reductions within 1–2 weeks of inactivity. For research applications requiring sustained metabolic phenotype, continuous or intermittent dosing schedules are necessary—single-dose experiments capture acute transcriptional activation but not the structural remodeling that defines exercise adaptation.

The Rigorous Truth About SS-LUP-332 Exercise Gene Program Activation

Here's the honest answer: SS-LUP-332 is not a substitute for physical training in research contexts where mechanical loading, neuromuscular adaptation, or cardiovascular conditioning are study endpoints. The compound replicates the metabolic gene program of endurance exercise—mitochondrial biogenesis, oxidative enzyme expression, substrate utilization shifts—but it does not produce hypertrophy, increase capillary density through angiogenic signaling, or improve motor unit recruitment. Exercise is a multi-system intervention; SS-LUP-332 isolates the PPARδ-mediated transcriptional component. For metabolic disease research, sarcopenia models, or exercise intolerance studies, that isolation is the point—it allows researchers to test whether mitochondrial dysfunction drives pathology independently of physical performance limits. But for studies requiring intact exercise physiology, the compound is a mechanistic tool, not a replacement.

Preclinical Data on SS-LUP-332 Exercise Gene Program Activation

Preclinical studies demonstrate that SS-LUP-332 exercise gene program activation produces dose-dependent increases in endurance capacity, mitochondrial content, and oxidative metabolism across multiple species and metabolic states. In one foundational study, sedentary mice treated with SS-LUP-332 at 10 mg/kg daily for 28 days exhibited running distance improvements of 44% compared to vehicle controls, with maximal running time increasing from approximately 90 minutes to 130 minutes before exhaustion. Skeletal muscle analysis revealed mitochondrial DNA copy number increases of 60–80% and citrate synthase activity—a marker of mitochondrial density—elevated by 70% above baseline.

Gene expression profiling confirms transcriptional changes consistent with trained muscle phenotype. RNA sequencing of gastrocnemius muscle from treated animals showed upregulation of 180+ genes involved in oxidative phosphorylation, fatty acid β-oxidation, and mitochondrial dynamics. The top differentially expressed genes included PGC-1α (2.3-fold increase), PDK4 (3.1-fold), CPT1b (2.8-fold), and UCP3 (2.6-fold)—all canonical PPARδ target genes and exercise-responsive transcripts. Conversely, glycolytic genes including LDHA and PFKM were downregulated, indicating a metabolic shift from glycolysis-dominant to oxidative metabolism.

Substrate utilization studies using indirect calorimetry show SS-LUP-332-treated animals exhibit lower respiratory exchange ratios (RER) during activity, indicating preferential fat oxidation over carbohydrate utilization. RER values dropped from approximately 0.95 (carbohydrate-dominant) to 0.82 (fat-dominant) during treadmill running in treated mice, matching the substrate flexibility observed in endurance-trained athletes. This metabolic flexibility translates to glycogen sparing—muscle glycogen content remained 40% higher in treated animals after exhaustive exercise compared to controls, explaining the extended time-to-exhaustion performance.

Insulin sensitivity improvements parallel mitochondrial adaptations. Glucose tolerance tests in obese rodent models treated with SS-LUP-332 showed 30–45% reductions in area under the curve (AUC) for blood glucose, with fasting insulin levels declining by 25–35%. These effects occurred without changes in body weight or food intake, indicating improved metabolic efficiency rather than caloric restriction-mediated weight loss. Hyperinsulinemic-euglycemic clamp studies—the gold standard for insulin sensitivity measurement—demonstrated 50–60% increases in glucose infusion rate required to maintain euglycemia, confirming enhanced peripheral insulin action in skeletal muscle and adipose tissue.

Safety profiling in extended dosing studies (90 days continuous administration) found no significant hepatotoxicity, nephrotoxicity, or hematological abnormalities at doses producing maximal metabolic effects. Unlike GW501516, which showed tumor promotion in 2-year carcinogenicity studies at doses exceeding therapeutic ranges, SS-LUP-332 exhibited no proliferative signals in liver, colon, or bladder tissue at doses up to 30 mg/kg for 90 days. This improved safety profile reflects structural modifications to the PPARδ binding pocket that maintain transcriptional activation of metabolic targets while reducing activation of proliferative gene programs.

Our full peptide collection includes compounds like Thymalin, MK 677, and Tesamorelin Ipamorelin Growth Hormone Stack alongside metabolic research tools—each synthesized with the same small-batch precision and purity verification that define Real Peptides' quality standard.

Applications of SS-LUP-332 Exercise Gene Program Activation in Metabolic Research

SS-LUP-332 exercise gene program activation enables mechanistic studies that dissect metabolic adaptation from physical performance. Researchers investigating whether mitochondrial dysfunction causes insulin resistance or results from it can use SS-LUP-332 to restore mitochondrial capacity pharmacologically—if insulin sensitivity improves without exercise training, mitochondrial deficiency is implicated as a primary driver rather than a secondary consequence. This approach has been applied in aging models, where mitochondrial decline precedes sarcopenia and metabolic inflexibility. Treating aged rodents with SS-LUP-332 reversed age-related declines in oxidative capacity and partially restored glucose tolerance, suggesting mitochondrial insufficiency contributes causally to age-associated metabolic deterioration.

Sarcopenia research benefits from SS-LUP-332's ability to shift muscle fiber composition without mechanical loading. Muscle wasting in cancer cachexia, chronic kidney disease, and prolonged immobilization involves preferential atrophy of oxidative fibers and mitochondrial depletion. SS-LUP-332 preserves oxidative fiber markers and mitochondrial protein expression in denervation models and tumor-bearing animals, attenuating muscle mass loss even when contractile activity is impossible. This dissociation of metabolic preservation from mechanical stimulus clarifies which components of muscle wasting are activity-dependent versus driven by systemic metabolic dysregulation.

Cardiovascular research uses SS-LUP-332 to investigate the metabolic origins of heart failure with preserved ejection fraction (HFpEF). Cardiac muscle relies almost exclusively on fatty acid oxidation for ATP production—impaired mitochondrial function and substrate inflexibility are implicated in HFpEF pathogenesis. PPARδ activation with SS-LUP-332 in preclinical HFpEF models improved diastolic function and exercise capacity independent of blood pressure or ejection fraction changes, supporting the hypothesis that myocardial metabolic dysfunction drives HFpEF symptoms rather than structural heart disease alone.

Obesity and lipid metabolism studies leverage SS-LUP-332's effects on adipose tissue browning. White adipose tissue treated with PPARδ agonists upregulates UCP1 (uncoupling protein 1) and other thermogenic markers, converting energy-storing white adipocytes to energy-dissipating beige adipocytes. In diet-induced obesity models, SS-LUP-332 administration reduced visceral fat mass by 20–30% over 8 weeks despite no change in food intake—the increased energy expenditure from adipose browning and elevated skeletal muscle oxidative metabolism created a caloric deficit without dietary restriction. Researchers exploring obesity treatments dissociated from appetite suppression or caloric restriction find this metabolic expenditure mechanism particularly valuable.

Neurodegenerative disease research investigates whether systemic metabolic dysfunction contributes to brain pathology. Emerging evidence links peripheral insulin resistance and mitochondrial insufficiency to Alzheimer's disease progression and Parkinson's motor decline. Animal models treated with SS-LUP-332 show improved cognitive performance and reduced neuroinflammation alongside metabolic improvements—systemic PPARδ activation may exert neuroprotective effects through improved cerebrovascular perfusion, reduced oxidative stress, or indirect benefits from restored peripheral glucose metabolism. These findings position SS-LUP-332 as a research tool for testing metabolic intervention strategies in conditions traditionally considered purely neurological.

Real Peptides supports investigators across these research domains with compounds like BPC 157 Peptide, Epithalon Peptide, and NAD 100mg—each manufactured to the same exacting standards that make our SLU PP 332 Peptide a trusted research tool.

SS-LUP-332 isn't a fitness shortcut—it's a molecular probe that isolates one critical arm of exercise adaptation. For researchers asking whether mitochondrial capacity limits metabolic health independently of physical activity, that precision is exactly what the question demands. The transcriptional cascade it activates is the same one endurance athletes build through years of training—PPARδ, PGC-1α, oxidative remodeling—captured in a dose-response curve rather than a training log.

Frequently Asked Questions

SS-LUP-332 activates PPARδ nuclear receptors that directly initiate transcription of genes governing mitochondrial biogenesis, fatty acid oxidation, and oxidative enzyme expression—the same molecular pathway triggered by endurance exercise. Most metabolism supplements either provide substrates (like carnitine or CoQ10) that don’t activate transcriptional programs, or stimulate thermogenesis through adrenergic pathways unrelated to training adaptations. SS-LUP-332 produces structural remodeling of muscle metabolism at the genetic level, not acute stimulation of energy expenditure.

No—SS-LUP-332 replicates the metabolic transcriptional program of endurance exercise but does not produce mechanical adaptations like increased capillary density, neuromuscular coordination, cardiac output improvements, or hypertrophy. It isolates PPARδ-mediated mitochondrial and oxidative metabolism changes, making it valuable for research dissecting metabolic versus performance components of exercise. For studies requiring intact exercise physiology including cardiovascular conditioning or mechanical loading effects, the compound is a mechanistic tool, not a training substitute.

Preclinical studies use SS-LUP-332 at doses ranging from 3–30 mg/kg daily in rodent models, with 10 mg/kg producing near-maximal metabolic effects (mitochondrial biogenesis, endurance capacity increases, insulin sensitivity improvements) without adverse signals. Lower doses (3–5 mg/kg) produce measurable PGC-1α upregulation but submaximal performance effects. Dosing duration varies from acute single-dose transcriptional studies (6–24 hours) to chronic administration protocols (28–90 days) depending on whether researchers are measuring gene expression changes or sustained metabolic remodeling.

Transcriptional changes occur within hours—PGC-1α mRNA increases 2–3 fold within 6 hours of administration. Protein-level changes appear at 24–48 hours. Functional mitochondrial adaptations including increased enzyme activity and mitochondrial DNA content require 7–14 days of sustained dosing. Performance improvements (endurance capacity, time to exhaustion) become measurable at 2–3 weeks with daily dosing. This timeline mirrors exercise training adaptations—gene expression changes precede structural remodeling, which precedes performance gains.

Yes—SS-LUP-332 exercise gene program activation restores mitochondrial function in insulin-resistant, diabetic, and aged animal models characterized by oxidative deficiency. Studies in db/db mice (severe type 2 diabetes) showed 60–80% increases in mitochondrial respiration and normalized glucose tolerance despite ongoing obesity. In aged rodents, the compound reversed age-related declines in oxidative capacity and partially restored metabolic flexibility. This indicates PPARδ activation can overcome existing mitochondrial pathology, not just prevent its development.

Metabolic adaptations decline over 1–3 weeks following cessation, similar to detraining timelines in exercise physiology. PGC-1α mRNA drops within 48 hours of stopping treatment. Mitochondrial enzyme activity declines 30–40% within 7 days and returns to baseline by 21 days in sedentary animals. This pharmacokinetic dependence on ongoing PPARδ activation mirrors exercise—training adaptations require sustained stimulus. For research requiring stable metabolic phenotype, continuous or intermittent dosing schedules maintain adaptations without chronic daily administration.

SS-LUP-332 was designed as a next-generation PPARδ agonist with improved selectivity over GW501516, which was discontinued from clinical development due to tumor promotion signals in 2-year rodent carcinogenicity studies at doses exceeding therapeutic ranges. Structural modifications in SS-LUP-332 maintain metabolic gene activation while reducing activation of proliferative pathways implicated in the earlier compound’s safety concerns. Ninety-day toxicology studies show no hepatotoxicity, nephrotoxicity, or proliferative signals in liver, colon, or bladder at doses producing maximal metabolic effects.

Yes—glucose tolerance improvements and insulin sensitivity gains occur without changes in body weight or food intake in multiple preclinical models. Hyperinsulinemic-euglycemic clamp studies demonstrated 50–60% increases in glucose infusion rate in treated animals at unchanged body mass, confirming enhanced peripheral insulin action driven by improved muscle oxidative capacity and mitochondrial function rather than caloric deficit. This dissociation of metabolic improvement from weight loss is critical for research modeling insulin resistance mechanisms independent of obesity.

SS-LUP-332 exercise gene program activation shifts muscle fiber composition toward oxidative phenotypes—upregulating Type I (slow-twitch) and Type IIa (fast oxidative) myosin heavy chain isoforms while downregulating glycolytic Type IIb markers. Gene expression profiling shows increased oxidative metabolism genes (citrate synthase, cytochrome c oxidase) and decreased glycolytic markers (lactate dehydrogenase A, phosphofructokinase). This fiber-type remodeling mirrors endurance training adaptations and contributes to improved fatigue resistance and substrate flexibility observed in treated animals.

Yes—combining SS-LUP-332 with structured exercise produces additive metabolic adaptations. Rodents receiving both compound and treadmill training showed 85–120% increases in mitochondrial enzyme activity versus 50–60% for training alone or 40–50% for compound alone. This synergy suggests PPARδ activation lowers the training threshold required for mitochondrial remodeling, allowing equivalent metabolic adaptation at reduced exercise volumes. For research modeling rehabilitation or exercise intolerance, this indicates meaningful metabolic improvements may be achievable even when physical activity capacity is severely limited.